SCMP Financial Facts
Research and development revenue: 2.8MWeighted average common shares outstanding - diluted: 41.46M
See Full Income Statement
Total stockholders' equity: 40M
Accrued expenses: 7.85M
See Full Balance Sheet
Earnings History for Sucampo Pharmaceuticals (SCMP)
|
Expand Research on SCMP
| Next EPS Date | 6/7/13 *Est. | EPS Growth Rate | +433.3% *Last Qtr. |
|---|---|---|---|
| Average EPS % Beat Rate | -308.3% | Revenue Growth Rate | +145.4% *Last Qtr. |
| Average % Move 1-Wk after EPS | +31.8% |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Estimize EPS/Revs | Gd. | % Since | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
3/13/13  |
 |
Q412 | $0.32 | $0.12 | +$0.20 | $34.9M | $32.21M | N/A / N/A | N/A | +80.8% | Details |
| 11/3/11 |
|
Q311 | -$0.10 | N/A | N/A | $14.37M | $20.9M | N/A / N/A | N/A | +123.8% | Details |
| 3/13/12 |
|
Q411 | $0.06 | N/A | N/A | $14.22M | $15.9M | N/A / N/A | N/A | +18.2% | Details |
| 3/3/11 |
|
Q410 | -$0.15 | -$0.01 | -$0.14 | $12.4M | $15.5M | N/A / N/A | N/A | +109.1% | Details |
